KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to $56.5 million.

  • Pacific Biosciences Of California's Cash & Equivalents fell 2758.97% to $56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.5 million, marking a year-over-year decrease of 2758.97%. This contributed to the annual value of $55.4 million for FY2024, which is 6922.37% down from last year.
  • Pacific Biosciences Of California's Cash & Equivalents amounted to $56.5 million in Q3 2025, which was down 2758.97% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Cash & Equivalents registered a high of $932.4 million during Q1 2021, and its lowest value of $54.8 million during Q2 2025.
  • For the 5-year period, Pacific Biosciences Of California's Cash & Equivalents averaged around $276.6 million, with its median value being $304.4 million (2022).
  • As far as peak fluctuations go, Pacific Biosciences Of California's Cash & Equivalents skyrocketed by 125400.95% in 2021, and later plummeted by 7977.9% in 2024.
  • Pacific Biosciences Of California's Cash & Equivalents (Quarter) stood at $460.7 million in 2021, then dropped by 29.44% to $325.1 million in 2022, then crashed by 44.66% to $179.9 million in 2023, then tumbled by 69.22% to $55.4 million in 2024, then increased by 1.98% to $56.5 million in 2025.
  • Its last three reported values are $56.5 million in Q3 2025, $54.8 million for Q2 2025, and $58.5 million during Q1 2025.